

# **AUTOLOGOUS CELL THERAPY CAPACITY PLANNING AND DEBOTTLENECKING USING SIMULATION AND OPTIMIZATION**

David Zhang, Bioproduction Group, Inc.  
david.zhang@bio-g.com

Key Words: autologous cell therapy, CAR-T, modeling, simulation, optimization, manufacturing, commercialization

Autologous cell therapy is a groundbreaking treatment for patients that also has distinct scale-up and commercialization challenges. In this presentation, we discuss the differences between traditional life science versus autologous manufacturing, the underlying mathematical theory, and the use of optimization and simulation to accurately identify and resolve the capacity issues unique to this market. We also look ahead to the future of autologous manufacturing and the issues that must be addressed as more drugs become available commercially worldwide.